Clinical Trial Design, Endpoints and Regulatory Considerations in Heart Failure
After the withdrawal of flosequinan in the early 1990s, because of an increased risk of mortality and fatal arrhythmias, the bar for the approval of new drugs in heart failure has beenraised and regulatory agencies have requested evidence for the efficacy of new treatments on mortality and morbidity...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Barcaray International
2019-01-01
|
| Series: | International Cardiovascular Forum Journal |
| Subjects: | |
| Online Access: | https://icfjournal.org/index.php/icfj/article/view/595/pdf |